港股異動 | 兆科眼科-B(6622.HK)續升超5% 近期股價走出深V反轉行情
格隆匯6月2日丨兆科眼科-B(6622.HK)自上市以來走勢波動較大,近期連續拉昇上揚,股價走出深V反轉行情。現漲5.3%,報13.9港元,總市值逾74億港元。高盛表示,看好兆科眼科業務增長前景,主因內地眼科藥物市場的巨大增長潛力、公司的創新和多目標管道輔以仿製藥以及其作為全球眼科資產進入內地渠道的潛力等因素,首予其買入評級及目標價20.29港元。於2021年5月13日,公司兩項藥品通過國家藥監局藥品註冊現場核查,預計2022年開始商業化。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.